Physician profile
Christopher Decotiis
NPI 1346401130
$6,871.86
in general payments reported to CMS, 2019-2025
21 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $42.25 · 2021: $110 · 2022: $190 · 2023: $377 · 2024: $5,254 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $1,672 · Travel and Lodging: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $1,672.19 |
| Travel and Lodging | $590.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,639.29 | 2024 | |
| Glaxosmithkline, LLC. | $1,035.37 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pulmonx Corporation | $251.42 | 2022-2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $157.52 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $128.22 | 2022-2025 | Dupixent |
| Genzyme Corporation | $123.89 | 2021-2025 | |
| Mylan Specialty L.P. | $111.45 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.45 | 2019-2022 | |
| Verona Pharma, INC. | $54.40 | 2025 | Ohtuvayre |
| Insmed, INC. | $39.43 | 2019-2020 | |
| Amgen INC. | $32.69 | 2023 | Tezspire |
| Genentech USA, INC. | $29.33 | 2021-2022 | |
| Optinose US, INC. | $28.99 | 2020-2021 | |
| Tempus Ai, INC | $28.78 | 2024 | |
| Shire North American Group INC | $26.23 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $22.04 | 2021 | |
| Philips North America LLC | $16.50 | 2025 | Vest Therapy Und |
| Merck Sharp & Dohme LLC | $16.45 | 2023 | |
| Advanced Respiratory, INC | $14.75 | 2021 | |
| Octapharma USA, INC. | $14.31 | 2022 | |
| Grifols USA, LLC | $13.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Decotiis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.